Practical Effect of Sorafenib Monotherapy on Advanced Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis
Open Access
- 15 November 2013
- journal article
- clinical trial
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 7 (6), 696-703
- https://doi.org/10.5009/gnl.2013.7.6.696
Abstract
We investigated the effects of sorafenib monotherapy on advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) in a clinical setting. In total, 143 consecutive patients with unresectable HCC were treated with sorafenib. Among these patients, 30 patients with advanced HCC and PVTT (Vp3 or 4) were treated with sorafenib monotherapy. All patients had a performance status of 1 to 2 (Eastern Cooperative Oncology Group 1/2, 20/10) and Child-Pugh class A or B (A/B, 17/13). Eleven patients had modified Union for International Cancer Control stage IVA tumors, whereas 19 had stage IVB tumors. All patients had PVTT (Vp3, 6; Vp4, 24). Following sorafenib monotherapy, three patients (10.0%) had a partial response with PVTT revascularization, and nine (30.0%) had stable disease, with a disease control rate of 33.3%. The median overall survival was 3.1 months (95% confidence interval [CI], 2.70 to 3.50), and the median progression-free survival was 2.0 months (95% CI, 1.96 to 2.05). Fatigue and hand-foot skin reactions were the most troublesome side effects. A limited proportion of patients with advanced HCC and PVTT exhibited a remarkable outcome after sorafenib monotherapy, although the treatment results in this type of patient is extremely poor. Further studies to predict good responders to personalized therapy are warranted.Keywords
This publication has 28 references indexed in Scilit:
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Genomics and Signaling Pathways in Hepatocellular CarcinomaSeminars in Liver Disease, 2007
- Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft modelsCancer Chemotherapy and Pharmacology, 2006
- Management of hepatocellular carcinomaHepatology, 2005
- Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2005
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- Hepatocellular carcinomaThe Lancet, 2003
- Clinical efficacy of portal vein stent placement in patients with hepatocellular carcinoma invading the main portal veinJournal of Hepatology, 1999
- A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patientsHepatology, 1998
- A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal veinCancer, 1997